Intellia Therapeutics, Inc.
NASDAQ:NTLABiotechnology
Healthcare
$9.52 +0.14%
+$0.02 today
- Market cap
- $1.34B
- Beta
- 1.81
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$3.33
52W Low $7.95High $28.25
Volume 9.96M
Average 6.11M
Income Statement
Follow revenue through to earnings.
Revenue
$67.67M
FY 2025 · Annual
+16.9% YoYOperating Income
-$440.99M
FY 2025 · Annual
Net Income
-$412.69M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.05M | 52.12M | 36.28M | 57.88M | 67.67M |
| Cost of Revenue | 6.89M | 7.57M | 8.98M | 10.29M | 15.92M |
| Gross Profit | 26.16M | 44.55M | 27.3M | 47.59M | 51.75M |
| Gross Margin | 79.2% | 85.5% | 75.3% | 82.2% | 76.5% |
| Research & Development | 229.81M | 419.98M | 435.07M | 466.31M | 388.86M |
| Selling, General & Admin | 71.1M | 90.31M | 116.5M | 125.83M | 119.8M |
| Operating Expenses | 294.01M | 502.71M | 542.59M | 581.86M | 492.74M |
| Depreciation & Amortization | 6.89M | 7.57M | 8.98M | 10.29M | 15.92M |
| EBITDA | (261M) | (466.61M) | (472.22M) | (508.74M) | (396.77M) |
| EBITDA Margin | -789.6% | -895.3% | -1301.8% | -879.0% | -586.3% |
| Operating Income | (267.85M) | (458.16M) | (515.29M) | (534.26M) | (440.99M) |
| Operating Margin | -810.4% | -879.0% | -1420.5% | -923.1% | -651.7% |
| Interest Income | 1.28M | 8.54M | 49.83M | 47.81M | 29.2M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (42K) | (16.02M) | 34.1M | 15.24M | 28.3M |
| Income Before Tax | (267.89M) | (474.19M) | (481.19M) | (519.02M) | (412.69M) |
| Pre-Tax Margin | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (267.89M) | (474.19M) | (481.19M) | (519.02M) | (412.69M) |
| Net Margin | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% |
| EPS (Basic) | (3.78) | (6.16) | (5.42) | (5.25) | (3.81) |
| EPS (Diluted) | (3.78) | (6.16) | (5.42) | (5.25) | (3.81) |
| 70.89M | 76.97M | 88.77M | 98.85M | 108.38M | |
| 70.89M | 76.97M | 88.77M | 98.85M | 108.38M |
NTLA Earnings Waterfall · TTM
NASDAQ:NTLA · Revenue to Net Income
Key Ratios
EPS$-3.54
Gross Margin-194.7%
Net Margin-625.4%
P/E Ratio-3.4
P/S Ratio87.4
Analysis
$66.1M of revenue converted into -$394.6M of net income for the selected period. Gross margin is -194.7% and net margin is -625.4%, showing how much revenue survives after costs and taxes. EPS is $-3.54, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K/A | 8-K/A filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 |
How much revenue does NTLA generate?
Intellia Therapeutics, Inc. (NTLA) reported $67.67M of revenue in fiscal 2025.
Is NTLA profitable?
Intellia Therapeutics, Inc. (NTLA) reported -$412.69M of net income, with a net margin of -609.9%.
Continue the stock analysis
Jump to another research area for this company.